In vivo deuterium depletion is a new proprietary procedure for the treatment and prevention of various types of cancer. The product is in the manufacturing, distribution and sales phase and is covered by four patents registered in more than 20 countries.

Investment capital will be used for:
1) Production plant: €500,000
2) Clinical trials: €1,000,000
3) Basic research: €500,000

We believe this project represents an exceptional opportunity. The project owner is forecasting a return on the total investment of €2,000,000 within 3 years. Potential investors are offered partial ownership in the company.